Dianthus Therapeutics (DNTH) Enterprise Value (2018 - 2025)

Dianthus Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$404.3 million for Q4 2025.

• In Q4 2025, Enterprise Value fell 46.89% year-over-year to -$404.3 million; the TTM figure through Dec 2025 stood at -$404.3 million (down 46.89% YoY), while the FY2025 annual figure was -$404.3 million, down 46.89% from the prior year.
• Enterprise Value for Q4 2025 stood at -$404.3 million, roughly flat from -$402.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$52.9 million in Q1 2023, with the low at -$404.3 million in Q4 2025.
• The 5-year median for Enterprise Value is -$191.2 million (2021), against an average of -$214.0 million.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 66.22% in 2023, then sank 612.8% in 2024.
• Dianthus Therapeutics' Enterprise Value stood at -$176.9 million in 2021, then jumped by 57.33% to -$75.5 million in 2022, then plunged by 130.12% to -$173.7 million in 2023, then plunged by 58.44% to -$275.2 million in 2024, then sank by 46.89% to -$404.3 million in 2025.
• Business Quant data shows DNTH's Enterprise Value at -$404.3 million in Q4 2025, -$402.6 million in Q3 2025, and -$257.4 million in Q2 2025.